Novo Nordisk’s Teen Trial Victory Can’t Mask the Storm Brewing in Canada

Novo Nordisk faces a mixed outlook: FDA approves oral Ozempic for teens, but Canadian generics and US price wars drive shares down 39%.

The Danish pharma giant is navigating a tale of two very different realities. On one hand, a breakthrough oral version of Ozempic has just secured FDA approval, and fresh clinical data shows it works wonders for adolescents. On the other, a generics assault in Canada and a blistering price war in the US pill market are carving deep wounds into the stock.

Shares in Novo Nordisk have tumbled nearly 39% over the past twelve months, landing at €35.16 — a far cry from their historic peak. Yet the last month has offered a sliver of relief, with the stock clawing back roughly 14%.

A Pill That Works for Teens

The FDA’s green light for a swallowable, once-daily version of Ozempic marks a pivotal shift for patients who have long relied on injections. US sales are slated to begin in the second quarter of 2026. But the company is already eyeing an even younger demographic.

Results from the PIONEER TEENS trial showed that the oral medication delivered a statistically significant reduction in blood sugar compared to a placebo in children and adolescents. Novo Nordisk plans to file for regulatory approval in this age group during the second half of the year. The strategy is clear: lock in market leadership before competitors can gain a foothold.

The management will present additional clinical data at a congress in Istanbul in mid-May, with a spotlight on Wegovy’s efficacy in women.

Generics Strike in Canada

While the pipeline looks promising, the present is proving far more hostile. Canada’s health authorities have approved the first generic version of semaglutide, manufactured by Dr. Reddy’s Laboratories. The original Ozempic patent expired in the country back in January.

Generic launches typically undercut the branded price by 25% to 35% when a single competitor enters the market. Once three or more players join the fray, prices can collapse to roughly 35% of the original. Canadian regulators are currently reviewing eight additional applications, meaning the price erosion could accelerate rapidly.

The Oral Pill Battle Heats Up

The competitive landscape is also shifting in the US, where Eli Lilly launched its own daily oral GLP-1 drug, Foundayo, at the end of April. The pill requires no restrictions on food or water intake, a convenience edge that could sway patients. Clinical data showed weight loss of around 12%, and self-pay patients face a monthly cost of up to $349.

Viking Therapeutics is preparing to enter Phase III trials by autumn 2026, adding another name to the crowded field.

Buyback Blitz and a Weak Outlook

In response to the mounting pressure, Novo Nordisk has announced a DKK 15 billion share buyback program. The move is designed to signal confidence and return capital to shareholders. Meanwhile, parent company Novo Holdings is investing roughly $72 million into a South Korean biotech fund.

But the financial picture remains cloudy. The company has guided for a full-year revenue decline of between 5% and 13%. Analysts have flagged a high debt load and a weak free cash flow that doesn’t fully cover current dividend payments.

Investors will get their next detailed look at the numbers on May 6, when first-quarter results are due. The market will be watching for early sales data on the new oral Ozempic in the US, as well as an update on production capacity constraints. A day later, on May 7, the company is expected to provide further color on the planned pediatric label expansion.